omniture
logo
Search
原启生物科技（上海）有限责任公司
Media Room

Latest News

rss

Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.

SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinic...

2024-01-29 21:08 1435

Oricell OriCAR-017 CAR-T Therapy Clears IND Hurdle, Paving the Way for Global Impact

SHANGHAI, Aug. 10, 2023 /PRNewswire/ -- August 10, 2023, in a groundbreaking development, Oricell T...

2023-08-10 21:00 2019

Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"),...

2023-02-28 21:00 2313

Oricell Publishes Data from POLARIS Clinical Study Evaluating OriCAR-017 in the Treatment of RRMM in The Lancet Haematology

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd (Oricell), an innovative phar...

2023-01-31 09:24 1678

OriCell Therapeutics Raises Over $120 Million in Series B Financing Led by Qiming Venture Partners and Quan Capital to Advance Cell Therapies for Cancer Immunology

2022 is set to be a milestone year for OriCell who has been focusing on the field of cancer immunot...

2022-08-01 22:00 2018

ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017

SHANGHAI, May 27, 2022 /PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovativ...

2022-05-27 21:49 2410

OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting

SHANGHAI, June 7, 2021 /PRNewswire/ -- On June 4, 2021 (EST), OriginCell Therapeutics (Shanghai) C...

2021-06-07 10:00 2856
OriginCell Therapeutics Presents Positive Results of GPC3 CAR-T in HCC Trial at the 2021 ASCO Annual Meeting